Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-16

Study Completion Date

2020-07-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clearing potential intrahepatic metastasis to prevent early recurrence after liver cancer treatment, there are no effective interventions so far. For secondary metastatic cancer, only the lesions visible under ultrasound can be used, one by one for local ablation and chemotherapy, but people may develop new tumor lesions. Therefore, the treatment of potential tumors and recurrent tumors after ablation is a very important clinical issue.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combined Treatment of RFA and Sorafenib on Recurrent HCC

NCT01470495

HCC Radiofrequency Ablation Sorafenib

UNKNOWN NA

Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)

NCT05277675

Hepatocellular Carcinoma Recurrent

UNKNOWN NA

Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma

NCT03988998

Hepatocellular Carcinoma

UNKNOWN PHASE3

RFA Versus SBRT for Recurrent Small HCC

NCT04047173

Hepatocellular Carcinoma

COMPLETED PHASE3

Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

NCT00019604

Liver Cancer Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Clearing potential intrahepatic metastasis to prevent early recurrence after liver cancer treatment, there are no effective interventions so far. For secondary metastatic cancer, only the lesions visible under ultrasound can be used, one by one for local ablation and chemotherapy, but people may develop new tumor lesions. Therefore, the treatment of potential tumors and recurrent tumors after ablation is a very important clinical issue. Therefore, this study will include primary liver cancer, as well as secondary metastatic malignant liver cancer, such as colorectal cancer, lung cancer, breast cancer, and other cancers with a high incidence in Chinese patients, and detection of immune cells by surgery, and through various biomarkers to explore its mechanism and efficacy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Radiofrequency Ablation

Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy

Group Type EXPERIMENTAL

Radiofrequency Ablation

Intervention Type PROCEDURE

The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.

Radiofrequency Ablation combine with Nivolumab

Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy, and improving immune systems by Nivolumab

Group Type PLACEBO_COMPARATOR

immunotherapy with Nivolumab

Intervention Type BIOLOGICAL

After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

immunotherapy with Nivolumab

After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.

Intervention Type BIOLOGICAL

Radiofrequency Ablation

The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Disease characteristics: Patients with primary or metastatic liver cancer judged by histology
* Age: 20 years old or older
* Life expectation: at least 3 months
* Hematology:

1. Platelet count: at least 50,000/mm\^3
2. Prothrombin time (PT) or partial thromboplastin time (PTT): no more than 1.5 times the control group
3. Creatinine: no more than 2.5 mg/dl
* No pregnancy, no rhythm adjuster or other implantable device
* There are no uncontrollable responses to this study
* Other malignant tumors, except for therapeutic non-melanoma skin cancer or cervical cancer 5 years before entering the study inside.
* The number of liver tumors is less than three, the size is less than three centimeters, or the size of a single tumor is less than five centimeters, and those who want to undergo radiofrequency ablation are treated.
* The clotting time is normal and the number of platelets needs to be greater than 50,000, total bilirubin is less than 3 mg/dl, controllable ascites, no extrahepatic metastasis and portal vein invasion, and those who want to undergo radiofrequency ablation.
* The patient refuses or is unable to perform surgery (eg, If the age is too old, for those who want to undergo radiofrequency ablation).
* Patients and their families must fully understand and agree to perform radiofrequency ablation procedures.

Exclusion Criteria

* There are people with central nervous system metastases.
* Measure lesions only by previous radiotherapy or topical treatment.
* Biliary obstruction did not undergo adequate drainage procedures prior to enrollment.
* White blood cells (WBC) are less than 3,500 / mm3 and absolute neutrophil count (ANC) is less than 1,500 / mm3, platelets less than 100,000 / mm3
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is greater than 5.0 times the upper limit of the normal range (ULN).
* Serum total bilirubin levels are equal to or greater than 2.0 mg / dl.
* Serum creatinine greater than 1.5 mg / dl.
* There are peripheral neuropathies greater than grade 1.
* Concomitant diseases that may accumulate via chemotherapy. For example, active, noncontrolled infection or other activity, non-control Systemic diseases such as congestive heart failure, angina pectoris, respiratory insufficiency, arrhythmia.
* Those who are treated concurrently with other research drugs or other anti-cancer therapies.
* Pregnant or lactating women, or women with fertility potential, unless reliable and appropriate methods of contraception are used.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No